Get the Stockscreener App
3.91
5.96%
0.22
Larimar Therapeutics Inc stock is traded at $3.91, with a volume of 1.42M.
It is up +5.96% in the last 24 hours and up +15.68% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
See More
Previous Close:
$3.69
Open:
$3.7
24h Volume:
1.42M
Relative Volume:
1.08
Market Cap:
$334.66M
Revenue:
-
Net Income/Loss:
$-36.95M
P/E Ratio:
-4.6548
EPS:
-0.84
Net Cash Flow:
$-33.46M
1W Performance:
-2.49%
1M Performance:
+15.68%
6M Performance:
+22.57%
1Y Performance:
-49.29%
1-Day Range:
$3.70
$4.045
1-Week Range:
$3.51
$4.12
52-Week Range:
$1.61
$9.50
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.91 | 333.80M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
Published on: 2025-08-18 04:14:31 - Newser
Strategies to average down on Larimar Therapeutics Inc.2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - Newser
Larimar Therapeutics Advances Nomlabofusp Program Toward 2026 FDA Filing - MSN
JMP Securities Cuts Larimar Therapeutics (NASDAQ:LRMR) Price Target to $18.00 - MarketBeat
Analyzing net buyer seller activity in Larimar Therapeutics Inc.2025 Market Overview & Safe Entry Point Identification - Newser
What are Larimar Therapeutics Inc.’s recent SEC filings showingStop Loss & Fast Gain Stock Tips - sundaytimes.kr
Multi asset correlation models including Larimar Therapeutics Inc.2025 Major Catalysts & Smart Money Movement Alerts - Newser
Is it time to cut losses on Larimar Therapeutics Inc.Weekly Volume Report & Daily Price Action Insights - Newser
What’s the recovery path for long term holders of Larimar Therapeutics Inc.Profit Target & Intraday High Probability Setup Alerts - Newser
Using R and stats models for Larimar Therapeutics Inc. forecastingJuly 2025 Summary & Scalable Portfolio Growth Methods - Newser
Larimar Therapeutics Advances Nomlabofusp Program Amid Financial Losses - The Globe and Mail
Why Larimar Therapeutics Inc. is moving todayJuly 2025 PreEarnings & Fast Entry High Yield Tips - Newser
Larimar Therapeutics reports Q2 EPS (41c), consensus (49c) - MSN
JMP Securities Lowers Price Target for Larimar Therapeutics (LRMR) | LRMR Stock News - GuruFocus
RSI Crosses Above 30 for Larimar Therapeutics Inc. — Reversal in SightJuly 2025 Macro Moves & High Accuracy Buy Signal Tips - 선데이타임즈
Top Analysts Pick 3 Stocks with 300% Upside Potential - AInvest
Larimar Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail
Larimar Therapeutics stock price target lowered to $18 at JMP By Investing.com - Investing.com Canada
Promising Advancements and Strategic Positioning Drive Buy Rating for Larimar Therapeutics - TipRanks
Larimar: Q2 Earnings Snapshot - Greenwich Time
Larimar Therapeutics Aligns with FDA Guidance, Revises Nomlabofusp Submission Timeline - MSN
What indicators show strength in Larimar Therapeutics Inc.Weekly Risk Summary & Short-Term Swing Trade Alerts - Newser
Larimar Therapeutics Stock Maintains Buy Rating on Promising Data and Optimistic Outlook. - AInvest
Larimar Therapeutics Receives Buy Rating from Citi with $12 Price Target - AInvest
Larimar Therapeutics stock holds Buy rating at Truist ahead of September data - Investing.com Nigeria
Larimar Therapeutics stock maintains Buy rating at Guggenheim ahead of key data - Investing.com Canada
Larimar Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Larimar Therapeutics: Operational Efficiency Gains Signal Resilience in a High-Risk Biotech Play - AInvest
Larimar Beats Q2 Loss Estimates - The Motley Fool
Larimar Beats Q2 Loss Estimates - Nasdaq
Larimar Therapeutics Reports Second Quarter 2025 Financial Results | LRMR Stock News - GuruFocus
Larimar Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewswire
Larimar's Friedreich's Ataxia Drug Nears BLA Filing as FDA Provides Clear Path Forward - Stock Titan
Larimar Therapeutics prices $60M stock offering - MSN
Visual trend scoring systems applied to Larimar Therapeutics Inc.Dollar Strength & Entry and Exit Point Strategies - Newser
Will Larimar Therapeutics Inc. stock recover after earnings300% Return Stock Forecast - thegnnews.com
Will Larimar Therapeutics Inc. benefit from rising consumer demandTop Earnings Growth Momentum Picks - newsyoung.net
Larimar Therapeutics: Institutional Confidence and Capital-Raising Strategy Signal Conviction in Long-Term Pipeline - AInvest
Institutional Investors Hold 40% Stake in Larimar Therapeutics - AInvest
With 40% stake, Larimar Therapeutics, Inc. (NASDAQ:LRMR) seems to have captured institutional investors' interest - Yahoo Finance
Larimar Therapeutics Insider Bought Shares Worth $30,000,000, According to a Recent SEC Filing - 富途牛牛
Larimar Therapeutics Sees Significant Stock Purchase by Director - AInvest
Larimar Therapeutics Stock (LRMR) Opinions on Public Offering Announcement - Quiver Quantitative
Mintz Advises on Larimar Therapeutics’ $69 Million Public Offering - Mintz
Massive Stock Purchase by Larimar Therapeutics Director! - TipRanks
Larimar therapeutics: Deerfield funds buy $10.8m in shares By Investing.com - Investing.com Canada
Larimar therapeutics: Deerfield funds buy $10.8m in shares - Investing.com India
Larimar Therapeutics stock price target lowered to $10 at Jones Trading - Investing.com Canada
Why is Larimar Therapeutics Inc. stock attracting strong analyst attentionCapitalize on high-growth stocks early - Jammu Links News
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):